Search filters

Filters
Clear All

Phase

  • 2
  • 3
  • 4
  • 3
  • 6
  • 18
  • 8
  • 1
  • 2
  • 15
  • 17
  • 1

Found 18 hematology trials

A listing of hematology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS)
18 years - 65 years
All genders
Interventional
This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation using human leukocyte antigen-mismatched unrelated donors for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children.
Learn More
Online study
100 years or below
Accepts healthy volunteer
Female
Phase 1
Test Trial - v7.0What is the purpose of this study?This study is a randomized, open label, multicenter Phase II trial to evaluate the efficacy and safety of botensilimab (a novel Fc enhanced Tree depleting anti-CTLA4) and balstilimab (a novel anti-PD1) relative to ipilimumab and nivolumab in treatment naïve patients with …
18 years or above
Male
Phase 3
Interventional
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in …
99 years or below
All genders
The ASH Registry d/b/a the ASH Research Collaborative (ASH RC), is a non-profit organization established by the American Society of Hematology (ASH) in 2018 that aims to improve the lives of those affected by blood diseases by fostering collaborative partnerships to accelerate progress in hematology. The s Data Hub, a …
 ONC201 in recurrent high-grade glioma
18 years - 99 years
All genders
Phase 2
This is a phase II, open-label study of ONC201 in adults with recurrent high- grade glioma. Subjects for this study will be recruited from the patient population that present to the Penn Brain tumor center- Department of Neurosurgery or Department of Medicine division of Hematology/ Oncology for evaluation and treatment …
 Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
18 years - 99 years
All genders
Phase 3
Interventional
The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.
99 years or below
All genders
Certain blood cancers are treat blood or bone marrow transplants. Sometimes the donor cells attack the recipient's body, called GVHD. Cyclophosphamide helps reduce the risk and severity of GVHD .Researchers want to learn if using a lower dose of cyclophosphamide may reduce the drug's side effects while maintaining its effectiveness.
 Study comparing the effect of crizanlizumab plus standard of care to standard of care alone on renal function in sickle cell disease patients,with chronic kidney disease due to sickle cell nephropathy (STEADFAST).
16 years - 99 years
All genders
Phase 2
The main purpose of the study is to explore the effect of crizanlizumab on kidney function in people with long-term kidney disease caused by SCD. Kidney function of patients who receive crizanlizumab in addition to any regularly prescribed medications will be compared to that of patients who receive their regularly …
 Study of INO-5401 Alone or INO-5401 in Combination with INO-9012 Followed by Electroporation in Adults with BRCA1 or BRCA2 Mutations
18 years - 99 years
All genders
Phase 1
The research study is being conducted to test an experimental vaccine to potentially prevent cancer for people with BRCA1 or BRCA2 mutations. This study will test if the vaccine is safe (without significant side effects) and test a new way of administering vaccines. It will also test whether the vaccine …
 LODESTAR: Study of Rucaparib as Treatment for SoliD Tumors Associated with DEleteriouS MuTations in Homologous RecombinAtion Repair Genes
18 years - 99 years
All genders
Phase 2
This is a Phase 2 multicenter, open-label study evaluating rucaparib as treatment for solid tumors associated with a deleterious mutation in Homologous Recombination Repair (HRR) genes. All patients will be required to have received prior treatment with at least 1 line of life-extending therapy (if available) or have a tumor …
1 - 10 of 18